Six Months of Treatment with the Endoscopic Duodenal-Jejunal Bypass Liner Does Not Lead to Decreased Systemic Inflammation in Obese Patients with Type 2 Diabetes |
| |
Authors: | Charlotte de Jonge Sander S. Rensen Hedwig M. A. D’Agnolo Nicole D. Bouvy Wim A. Buurman Jan Willem M. Greve |
| |
Affiliation: | 1. Department of General Surgery and NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands 2. Department of General Surgery, Atrium Medical Center Parkstad, Henri Dunantstraat 5, 6419 PC, Heerlen, The Netherlands 3. Department of General Surgery, Atrium Medical Center Parkstad, PO Box 4446, 6401 CX, Heerlen, The Netherlands
|
| |
Abstract: | Obesity is associated with chronic low-grade systemic inflammation. Bariatric surgery has been shown to reduce this inflammation. Here, the effect of a nonsurgical bariatric technique, the duodenal-jejunal bypass liner (DJBL), on systemic inflammation was investigated. Seventeen obese patients with type 2 diabetes were treated with the DJBL for 6 months. Plasma C-reactive protein (CRP), myeloperoxidase (MPO), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) were determined prior to and during DJBL treatment. Three months after initiation of DJBL treatment, TNF-α levels had increased from 1.8?±?0.1 to 2.1?±?0.1 pg/mL, whereas IL-6 increased from 2.7?±?0.3 to 4.0?±?0.5 pg/mL (both p?0.05). CRP and MPO also increased, though the differences were not significant. After 6 months, the levels of all parameters were similar to baseline levels (CRP, 4.2?±?0.6 mg/L; TNF-α, 2.0?±?0.1 pg/mL; IL-6, 3.5?±?0.5 pg/mL; MPO, 53.6?±?ng/mL; all p?=?ns compared to baseline). In the current study, 6 months of endoscopic DJBL treatment did not lead to decreased systemic inflammation. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|